問卷
Log In
繁中 EN
TPIDB
TPIDB Outstanding PI
TPIDB > Study Site

Study Site



Linkou Chang Gung Medical Foundation

  • 0

    Total Beds

  • 0

    Total Doctors

  • 244New Taipei CityLinkou

Recruiting Trial

991Cases

篩選

Developmental Phase

  • Phase I

  • Phase I/II

  • Phase II

  • Phase II/III

  • Phase III

  • Phase IV

  • Others

Trial Status

  • Not yet recruiting

  • Active

  • Completed

Recruitment Status

  • Not yet recruiting

  • Recruiting

  • Completed

  • Terminated

  • Stop recruiting

  • Suspended

  • Study ended

Trial scale

  • Multi-Regional Multi-Center

  • Taiwan Multiple Center

  • Taiwan Single Center

The expected start time interval of the test

-

Trial Applicant

  • Hospital/Foundation

  • Pharmaceutical/Biopharmaceutical company

  • Contract Research Organization

Important Roles

  • Asia Regional PI

  • Taiwan National PI

  • Chairman/Global PI

  • Steering Committee

  • Advisory board

  • None

Audit by Sponsors/CRO

  • Sponsors

  • CRO

  • None

Investigator-initiated trial(IIT)

  • Yes

Filters

List

2436Cases

2016-04-01 - 2018-12-04

Phase I

Phase I Study of NC-6004 in Combination with 5-FU and Cetuximab as First-line Treatment in Patients with Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Condition/Disease

    Recurrent and/or Metastatic Squamous Cell Carcinoma of the Head and Neck

  • Test Drug

    NC-6004

Participate Sites
3Sites

Terminated3Sites

楊慕華
Taipei Veterans General Hospital

Division of Hematology & Oncology

王宏銘
Linkou Chang Gung Medical Foundation

Division of Hematology & Oncology

2010-12-01 - 2012-07-30

Phase II

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2010-12-01 - 2020-12-07

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
9Sites

Terminated6Sites

Suspended3Sites

2011-10-01 - 2013-03-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
8Sites

Terminated8Sites

2013-10-01 - 2020-07-31

Phase III

A Phase III, Open-label, Randomized Study of the Combination Therapy With NC-6004 and Gemcitabine Versus Gemcitabine Alone in Patients With Locally Advanced or Metastatic Pancreatic Cancer

  • Condition/Disease

    Locally Advanced or Metastatic Pancreatic Cancer

  • Test Drug

    NC-6004

Participate Sites
17Sites

Terminated17Sites

蘇五洲
National Taiwan University Hospital

Division of Hematology & Oncology

2006-08-01 - 2009-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Terminated12Sites

2009-08-01 - 2011-06-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
2Sites

Terminated2Sites

2009-10-01 - 2011-12-31

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
6Sites

Terminated6Sites

2009-03-01 - 2011-04-30

Others

  • Condition/Disease

  • Test Drug

Participate Sites
4Sites

Terminated4Sites

2021-09-01 - 2022-11-30

Phase III

  • Condition/Disease

  • Test Drug

Participate Sites
12Sites

Recruiting10Sites

Terminated2Sites

1 237 238 239 240 241 244
聯絡我們

台灣臨床試驗主持人資料庫 TPIDB

All Contents Copyright 2020 台灣臨床試驗主持人資料庫TPIDB